ArticleAmerican journal of clinical and experimental immunology2012
Anti-cytokine autoantibodies in autoimmune diseases.
Article in American journal of clinical and experimental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.PloS one · 2020Trial
- GM-CSF orchestrates monocyte and granulocyte responses to Cryptococcus gattii.PLoS pathogens · 2026Article
- Role of Diabetes and its metabolic pathways in Epilepsy: An insight to various target approaches.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Cytokine Signature Unveils Subgroups of Patients With Immune-Mediated Sensory Neuronopathies.Journal of the peripheral nervous system : JPNS · 2025Article
- Direct presentation of inflammation-associated self-antigens by thymic innate-like T cells induces elimination of autoreactive CD8Nature immunology · 2024Article
- Anti-cytokine autoantibodies: mechanistic insights and disease associations.Nature reviews. Immunology · 2024Review
- Clinical Significance of Uncommon, Non-Clinical, and Novel Autoantibodies.ImmunoTargets and therapy · 2024Review
- IL-1RA autoantibodies: insights into mechanisms and associated diseases.American journal of translational research · 2024Review
- Autoantibodies to Interferons in Infectious Diseases.Viruses · 2023Review
- Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.Annals of the rheumatic diseases · 2023Article
- Physiological Changes in the Levels of Anti-Cytokine Autoantibodies in Early Pregnancy Are Missing in Pregnant Women with Hashimoto's Thyroiditis.Journal of immunology research · 2023Article
- High-throughput identification of autoantibodies that target the human exoproteome.Cell reports methods · 2022Article
- Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity.The Journal of allergy and clinical immunology · 2022Review
- Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease.The Journal of allergy and clinical immunology · 2022Article
- Profiling Serum Cytokines and Anticytokine Antibodies in Psoriasis Patients.Journal of immunology research · 2022Article
- TheNeural regeneration research · 2021Review
- The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review.Frontiers in immunology · 2021Review
- Genetic-Code-Expansion Strategies for Vaccine Development.Chembiochem : a European journal of chemical biology · 2020Review
- Functional Analysis of Anti-cytokine Autoantibodies Using Flow Cytometry.Frontiers in immunology · 2019Review
- Autoantibodies against interleukin-21 correlate with disease activity in patients with rheumatoid arthritis.Clinical rheumatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An overview of the current literature is showing that autoantibodies (AutoAbs) against cytokines are produced in several pathological conditions, including autoimmune diseases, but can also be detected in healthy individuals. In autoimmune diseases, these AutoAbs may also be prognostic markers, either negative (such as AutoAbs to IL-8 and IL-1α in rheumatoid arthritis) or positive (such as AutoAbs to IL-6 in systemic sclerosis and those to osteopontin in rheumatoid arthritis). They may have neutralizing activity and influence the course of the physiological and pathological immune responses. High levels of AutoAbs against cytokines may even lead to immunodeficiency, such as those to IL-17 in autoimmune polyendocrine syndrome type I or those to IFN-γ in mycobacterial infections. Their role in human therapy may be exploited not only through passive immunization but also through vaccination, which may improve the costs for long lasting treatments of autoimmune diseases. Detection and quantification of these AutoAbs can be profoundly influenced by the technique used and standardization of these methods is needed to increase the value of their analysis.
Indexed as
Identifiers
23885320PMC3714194W1591908466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.